Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
33
IMNN Quote, Financials, Valuation and Earnings
Last price:
$3.17
Seasonality move
:
294.98%
Day range:
$3.14 - $3.71
52-week range:
$3.14 - $41.22
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
16.43x
P/B ratio:
1.72x
Volume:
88.1K
Avg. volume:
38.4K
1-year change:
-68.86%
Market cap:
$7M
Revenue:
--
EPS (TTM):
-$6.96
Analysts' Opinion
-
Consensus RatingImunon, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $64.47, Imunon, Inc. has an estimated upside of 1847.66% from its current price of $3.31.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $3.31.
Fair Value
-
According to the consensus of 3 analysts, Imunon, Inc. has 1847.66% upside to fair value with a price target of $64.47 per share.
IMNN vs. S&P 500
-
Over the past 5 trading days, Imunon, Inc. has underperformed the S&P 500 by -15.67% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Imunon, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Imunon, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Imunon, Inc. reported revenues of --.
Earnings Growth
-
Imunon, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Imunon, Inc. reported earnings per share of -$1.16.
Enterprise value:
2.9M
EV / Invested capital:
0.55x
Price / LTM sales:
16.43x
EV / EBIT:
--
EV / Revenue:
19.57x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.19x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$694.9K
Return On Assets:
-146.98%
Net Income Margin (TTM):
--
Return On Equity:
-365%
Return On Invested Capital:
-282.76%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $125K | -- | -- | -- | -- | |
| Gross Profit | -$484K | -$693.4K | -$694.9K | -$189.2K | -$167K | |
| Operating Income | -$22M | -$21M | -$14.5M | -$5M | -$3.5M | |
| EBITDA | -$21.2M | -$20.3M | -$13.8M | -$4.8M | -$3.3M | |
| Diluted EPS | -$3.43 | -$1.89 | -$6.96 | -$0.34 | -$1.16 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $56.8M | $40.2M | $21.7M | $12.5M | $7.3M | |
| Total Assets | $79.5M | $60.5M | $24.7M | $14.4M | $9M | |
| Current Liabilities | $6.5M | $8.5M | $5.3M | $5.4M | $4.2M | |
| Total Liabilities | $20.1M | $19.2M | $6.6M | $6.2M | $4.9M | |
| Total Equity | $59.3M | $41.4M | $18.1M | $8.2M | $4.1M | |
| Total Debt | $6.2M | $6M | $1.3M | $757.7K | $708.1K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$20.3M | -$18.2M | -$14.7M | -$4.1M | -$4.4M | |
| Cash From Investing | $3.5M | $6.5M | -$291.9K | -$2.9K | -- | |
| Cash From Financing | -$3.2M | $9.1M | $9.9M | $9.1M | $5M | |
| Free Cash Flow | -$20.8M | -$18.2M | -$15M | -$4.1M | -$4.4M | |
IMNN
Sector
Market Cap
$7M
$27.8M
Price % of 52-Week High
8.03%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-90.34%
-1.55%
1-Year Price Total Return
-68.86%
-17.47%
Beta (5-Year)
1.937
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.81
200-day SMA
Sell
Level
$8.60
Bollinger Bands (100)
Sell
Level
3.97 - 6.09
Chaikin Money Flow
Sell
Level
-7M
20-day SMA
Sell
Level
$3.91
Relative Strength Index (RSI14)
Sell
Level
27.87
ADX Line
Sell
Level
20.31
Williams %R
Buy
Level
-85.9504
50-day SMA
Sell
Level
$4.18
MACD (12, 26)
Sell
Level
-0.14
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Neutral
Level
57.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-63.3948)
Sell
CA Score
(Annual)
Level (-5.6553)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (11.3015)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
Stock Forecast FAQ
In the current month, IMNN has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The IMNN average analyst price target in the past 3 months is $64.47.
-
Where Will Imunon, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Imunon, Inc. share price will rise to $64.47 per share over the next 12 months.
-
What Do Analysts Say About Imunon, Inc.?
Analysts are divided on their view about Imunon, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Imunon, Inc. is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Imunon, Inc.'s Price Target?
The price target for Imunon, Inc. over the next 1-year time period is forecast to be $64.47 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is IMNN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Imunon, Inc. is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IMNN?
You can purchase shares of Imunon, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Imunon, Inc. shares.
-
What Is The Imunon, Inc. Share Price Today?
Imunon, Inc. was last trading at $3.17 per share. This represents the most recent stock quote for Imunon, Inc.. Yesterday, Imunon, Inc. closed at $3.31 per share.
-
How To Buy Imunon, Inc. Stock Online?
In order to purchase Imunon, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get IMNN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IMNN
Sector
P/E ratio
--
23.89x
PEG ratio
0.00x
-0.01x
P/B ratio
1.72x
1.82x
Price / LTM sales
16.43x
1.60x
Growth Metrics
IMNN
Sector
Revenue growth
--
4.62%
Earnings growth
-247.32%
10.88%
Revenue (5-year growth)
-100%
6.5%
Earnings forecast
-$1.82
-$0.21
Profitability
IMNN
Sector
Profitability FY 2024
-$718.1K
$3.5M
Return on invested capital
-282.76%
-31.77%
Return on assets
-146.98%
-27.96%
Return on equity
-365%
-37.63%
Earnings Date
Last Earnings Date
Nov
14
Next Earnings Date
Dec
26
Estimated Next Earnings Date
Mar
27
Balance Sheet
IMNN
Sector
Total cash
$5.3M
$26.3M
Short term investments
--
$25.7M
Total assets
$9.7M
$78M
Long term debt
$708.1K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 1.54% over the past day.
Buy
64
ZCSH alert for Dec 26
Grayscale Zcash Trust (ZEC) [ZCSH] is down 3.73% over the past day.
Buy
60
AAOI alert for Dec 26
Applied Optoelectronics, Inc. [AAOI] is down 9.39% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
